Invitae corporation associates with Pacific Biosciences to develop whole genome sequencing for epilepsy


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Invitae corporation associates with Pacific Biosciences to develop whole genome sequencing for epilepsy
Invitae and Pacific Biosciences collaborate to develop whole genome sequencing-based assays for pediatric epilepsy diagnostics

Invitae Corporation, a leading genetics company, and Pacific Biosciences of California, Inc., a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, announced a research collaboration focused on the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy. To support this collaboration, Invitae is expanding their PacBio sequencing capacity to meet the growing demand for clinical applications dependent on highly accurate genomic information.

More than half of epilepsies can be traced to a genetic cause. When a child presents with seizures, genetic testing can help identify more than 100 underlying, often rare conditions. Early genetic testing may be the most cost-effective, direct, and accurate diagnostic tool for children, shortening lengthy diagnostic odysseys. Delays in diagnosis can be devastating for children, as some genetic epilepsies are neurodegenerative and early symptoms may be subtle and easy to misdiagnose. Invitae’s Behind the Seizure program is a prominent collaborative program that was developed to provide faster diagnosis for young children with epilepsy in many regions around the world.

“It is estimated that nearly 50 million people are living with diagnosed epilepsy worldwide, but the underlying cause remains unknown for approximately half of these individuals,” said Robert L. Nussbaum, MD, Chief Medical Officer at Invitae. “Identifying the many underlying genetic causes of epilepsy is becoming increasingly critical to overall clinical management and prognosis. Through this research collaboration with PacBio, Invitae aims to develop innovative methods that will provide more accurate answers to individuals living with epilepsy and their healthcare providers.”

The first phase of the research collaboration between Invitae and PacBio is focused on a whole genome sequencing study of a large pediatric epilepsy patient cohort, derived from the Behind the Seizure program. Sequencing will be performed using PacBio’s highly accurate, long-read SMRT Sequencing technology, known as HiFi sequencing, to generate comprehensive variant profiles used to investigate the genetic etiology of epilepsy. This research is intended to accelerate Invitae’s development of assays to help patients that have been unable to get a diagnosis with conventional short-read sequencing technologies and facilitate improved treatment options based on specific genetic targets.

"We are honored to partner with Invitae, a recognized leader in genetics, to co-develop methods that have the potential to support earlier genetic testing and intervention to aid treatment selection for millions of people living with epilepsy worldwide,” said Christian Henry, Chief Executive Officer of PacBio. “Working with leading organizations such as Invitae is an important part of our strategy to accelerate the use of our highly accurate long-read sequencing platform in large-scale whole genome sequencing initiatives.”

Behind the Seizure is an innovative, cross-company collaboration designed to increase access to genetic testing for children who experience unprovoked seizures in childhood in the United States and Canada. More than half of epilepsies have some genetic basis, and are often associated with rare, neurodegenerative conditions with non-specific symptoms. Early genetic testing may be the most direct, cost-effective, and accurate diagnostic tool. Participants in the Behind the Seizure program are diagnosed one to two years sooner than reported averages. The program was established by BioMarin and Invitae and now includes: Biogen, Encoded Therapeutics, Neurocrine Biosciences, Neurogene Inc., Praxis Precision Medicines, PTC Therapeutics, Stoke Therapeutics, Taysha Gene Therapies, and Xenon Pharmaceuticals. 

Tags : #InvitaeCorporation #LatestNewsonInvitaeCorporation23rdOct #PacificBiosciences #LatestNewsonPacificBiosciences23rdOct #LatestPharmaCollaborationNews23rdOct #PediatricEpilepsy #GeneticTesting #RobertLNussbaum #ChristianHenry

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026